Amneal Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M | $341.4M | $151.2M | $213.4M |
| Accounts Receivable | — | — | — | $741.8M | $662.6M | $638.9M | $604.4M | $481.5M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M | $490.6M | $381.1M | $457.2M |
| Total Current Assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B | $1.55B | $1.21B | $1.29B |
| Property, Plant & Equipment | $443.0M | $424.9M | $447.6M | $469.8M | $514.2M | $477.8M | $478.0M | $544.1M |
| Goodwill | $595.5M | $597.4M | $598.6M | $598.9M | $593.0M | $522.8M | $419.5M | $426.2M |
| Intangible Assets (Excl. Goodwill) | $563.5M | $732.4M | $890.4M | $1.10B | $1.17B | $1.30B | $1.38B | $1.65B |
| Total Assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B | $3.67B | $4.35B |
| Liabilities | ||||||||
| Accounts Payable | — | — | — | $166.0M | $131.1M | $153.1M | $103.0M | $114.8M |
| Total Current Liabilities | $881.6M | $1.13B | $846.6M | $752.8M | $677.2M | $676.9M | $550.4M | $553.9M |
| Long-Term Debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.68B | $2.74B | $2.61B | $2.63B |
| Total Liabilities | $3.75B | $3.61B | $3.45B | $3.50B | $3.58B | $3.70B | $3.43B | $3.85B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-535.0M | $-607.1M | $-490.2M | $-406.2M | $-276.2M | $-286.8M | $-377.9M | $-20.9M |
| Total Stockholders' Equity | $-70.8M | $-109.3M | $19.8M | $298.4M | $360.3M | $303.3M | $232.0M | $504.8M |